Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β.

Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC Jr, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B.

Invest New Drugs. 2018 Dec;36(6):1103-1109. doi: 10.1007/s10637-018-0672-z. Epub 2018 Oct 11.

PMID:
30311036
2.

Energetic eruptions leading to a peculiar hydrogen-rich explosion of a massive star.

Arcavi I, Howell DA, Kasen D, Bildsten L, Hosseinzadeh G, McCully C, Wong ZC, Katz SR, Gal-Yam A, Sollerman J, Taddia F, Leloudas G, Fremling C, Nugent PE, Horesh A, Mooley K, Rumsey C, Cenko SB, Graham ML, Perley DA, Nakar E, Shaviv NJ, Bromberg O, Shen KJ, Ofek EO, Cao Y, Wang X, Huang F, Rui L, Zhang T, Li W, Li Z, Zhang J, Valenti S, Guevel D, Shappee B, Kochanek CS, Holoien TW, Filippenko AV, Fender R, Nyholm A, Yaron O, Kasliwal MM, Sullivan M, Blagorodnova N, Walters RS, Lunnan R, Khazov D, Andreoni I, Laher RR, Konidaris N, Wozniak P, Bue B.

Nature. 2017 Nov 8;551(7679):210-213. doi: 10.1038/nature24030.

PMID:
29120417
3.

Cation-π and CH-π Interactions in the Coordination and Solvation of Cu(+)(acetylene)n Complexes.

Brathwaite AD, Ward TB, Walters RS, Duncan MA.

J Phys Chem A. 2015 Jun 4;119(22):5658-67. doi: 10.1021/acs.jpca.5b03360. Epub 2015 May 15.

PMID:
25951753
4.

Opportunities for improvement: experience at one institution.

Walters RS.

J Natl Compr Canc Netw. 2014 Feb;12 Suppl 1:S36-9.

PMID:
24614051
5.

Developing a system to track meaningful outcome measures in head and neck cancer treatment.

Walters RS, Albright HW, Weber RS, Feeley TW, Hanna EY, Cantor SB, Lewis CM, Burke TW.

Head Neck. 2014 Feb;36(2):226-30. doi: 10.1002/hed.23290. Epub 2013 Jun 1.

PMID:
23729280
6.

Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.

Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU.

J Clin Oncol. 2012 Mar 20;30(9):930-5. doi: 10.1200/JCO.2011.36.2079. Epub 2012 Feb 13.

PMID:
22331946
7.

Infrared spectroscopy of small protonated water clusters, H(+)(H2O)n (n = 2-5): isomers, argon tagging, and deuteration.

Douberly GE, Walters RS, Cui J, Jordan KD, Duncan MA.

J Phys Chem A. 2010 Apr 8;114(13):4570-9. doi: 10.1021/jp100778s.

PMID:
20232806
8.

Configurationally stable longitudinally twisted polycyclic aromatic compounds.

Walters RS, Kraml CM, Byrne N, Ho DM, Qin Q, Coughlin FJ, Bernhard S, Pascal RA Jr.

J Am Chem Soc. 2008 Dec 3;130(48):16435-41. doi: 10.1021/ja806958x.

PMID:
18998648
9.

NCCN Task Force Report: Oral chemotherapy.

Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, Langbaum TS, Leedy RD, Muller RJ, Newcomer LN, O'Brien S, Reinke D, Rubino M, Saltz L, Walters RS.

J Natl Compr Canc Netw. 2008 Mar;6 Suppl 3:S1-14. Review.

PMID:
18377852
10.

Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.

Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN, Valero V.

Cancer. 2008 Apr 1;112(7):1455-61. doi: 10.1002/cncr.23321.

11.

Computational design of peptides that target transmembrane helices.

Yin H, Slusky JS, Berger BW, Walters RS, Vilaire G, Litvinov RI, Lear JD, Caputo GA, Bennett JS, DeGrado WF.

Science. 2007 Mar 30;315(5820):1817-22.

12.

Infrared photodissociation spectroscopy of Mg(+)(H2O)Ar(n) complexes: isomers in progressive microsolvation.

Walker NR, Walters RS, Tsai MK, Jordan KD, Duncan MA.

J Phys Chem A. 2005 Aug 18;109(32):7057-67.

PMID:
16834068
13.

Vibrational spectroscopy and structures of Ni+(C2H2)(n) (n =1-4) complexes.

Walters RS, Pillai ED, Schleyer PV, Duncan MA.

J Am Chem Soc. 2005 Dec 7;127(48):17030-42.

PMID:
16316250
14.

Solvation dynamics in Ni+ (H2O)n clusters probed with infrared spectroscopy.

Walters RS, Pillai ED, Duncan MA.

J Am Chem Soc. 2005 Nov 30;127(47):16599-610.

PMID:
16305249
15.

Spectral signatures of hydrated proton vibrations in water clusters.

Headrick JM, Diken EG, Walters RS, Hammer NI, Christie RA, Cui J, Myshakin EM, Duncan MA, Johnson MA, Jordan KD.

Science. 2005 Jun 17;308(5729):1765-9. Erratum in: Science. 2005 Aug 26;309(5739):1326.

16.

Structural trends in transition metal cation-acetylene complexes revealed through the C-H stretching fundamentals.

Walters RS, Schleyer PV, Corminboeuf C, Duncan MA.

J Am Chem Soc. 2005 Feb 2;127(4):1100-1.

PMID:
15669839
17.

Growth dynamics and intracluster reactions in Ni+(CO2)n complexes via infrared spectroscopy.

Walker NR, Walters RS, Grieves GA, Duncan MA.

J Chem Phys. 2004 Dec 1;121(21):10498-507.

PMID:
15549932
18.

Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer.

Gonzalez-Angulo AM, Walters RS, Carpenter RJ Jr, Ross MI, Perkins GH, Gwyn K, Theriault RL.

Clin Breast Cancer. 2004 Oct;5(4):317-9. Review.

PMID:
15507181
19.

Infrared photodissociation spectroscopy of V+(CO2)n and V+(CO2)nAr complexes.

Walker NR, Walters RS, Duncan MA.

J Chem Phys. 2004 Jun 1;120(21):10037-45.

PMID:
15268025
20.

Infrared signature of structures associated with the H+(H2O)n (n = 6 to 27) clusters.

Shin JW, Hammer NI, Diken EG, Johnson MA, Walters RS, Jaeger TD, Duncan MA, Christie RA, Jordan KD.

Science. 2004 May 21;304(5674):1137-40. Epub 2004 Apr 29.

21.

Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation.

Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL 3rd, Willey J, Bast R, Hortobagyi GN.

Cancer Invest. 2001;19(5):459-66.

PMID:
11458813
22.

Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer.

Ibrahim NK, Valero V, Theriault RL, Willey J, Walters RS, Buzdar AU, Booser DJ, Hortobagyi GN.

Am J Clin Oncol. 2000 Apr;23(2):117-21.

PMID:
10776969
23.

Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer: a phase II study.

Booser DJ, Walters RS, Holmes FA, Hortobagyi GN.

Am J Clin Oncol. 2000 Feb;23(1):40-1.

PMID:
10683074
24.

Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.

Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Gibbs H, Fraschini G, Buzdar AU, Willey J, Frye D, Asmar L, Hortobagyi GN.

Ann Oncol. 1999 Apr;10(4):403-11.

25.

Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.

Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW, Hortobagyi GN.

J Clin Oncol. 1999 May;17(5):1425-34.

PMID:
10334527
26.

Daily oral etoposide in patients with heavily pretreated metastatic breast cancer.

Pusztai L, Walters RS, Valero V, Theriault RL, Hortobagyi GN.

Am J Clin Oncol. 1998 Oct;21(5):442-6.

PMID:
9781596
27.

Phase II study of ifosfamide and mesna in patients with metastatic breast cancer.

Walters RS, Holmes FA, Valero V, Esparza-Guerra L, Hortobagyi GN.

Am J Clin Oncol. 1998 Aug;21(4):413-5.

PMID:
9708645
28.
29.

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.

Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN.

J Clin Oncol. 1996 Oct;14(10):2713-21.

PMID:
8874332
30.

Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome.

Ibrahim NK, Frye DK, Buzdar AU, Walters RS, Hortobagyi GN.

Arch Intern Med. 1996 Apr 22;156(8):882-8.

PMID:
8774207
31.

A phase II study of CI-973 [SP-4-3(R)]-1,1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N') platinum in patients with refractory advanced breast cancer.

Theriault RL, Walters RS, Holmes FA, Esparza-Guerra L, Kowal C, Hortobagyi GN.

Cancer Chemother Pharmacol. 1996;38(3):289-91.

PMID:
8646805
32.

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.

Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN.

J Clin Oncol. 1995 Dec;13(12):2886-94.

PMID:
8523051
33.

Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer.

Walters RS, Theriault RL, Booser DJ, Esparza L, Hortobagyi GN.

J Immunother Emphasis Tumor Immunol. 1995 Oct;18(3):185-7.

PMID:
8770774
34.

Phase II study of recombinant alpha-interferon and recombinant interleukin-2 metastatic breast cancer.

Walters RS, Theriault RL, Holmes FA, Esparza L, Hortobagyi GN.

J Immunother Emphasis Tumor Immunol. 1994 Nov;16(4):303-5.

PMID:
7881639
35.

The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer.

Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Fraschini G, Buzdar AU, Frye D, Gibbs HR, Hortobagyi GN.

J Natl Cancer Inst Monogr. 1993;(15):161-9.

PMID:
7912522
36.

Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer.

Benvenuto JA, Newman RA, Bignami GS, Raybould TJ, Raber MN, Esparza L, Walters RS.

Invest New Drugs. 1992 Jul;10(2):113-7.

PMID:
1500265
37.

Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer.

Walters RS, Theriault RL, Holmes FA, Hortobagyi GN, Esparza L.

Invest New Drugs. 1992 Apr;10(1):43-4.

PMID:
1376723
38.

A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma.

Walters RS, Frye D, Buzdar AU, Holmes FA, Hortobagyi GN.

Cancer. 1992 Jan 15;69(2):476-81.

PMID:
1728377
39.

Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN.

J Natl Cancer Inst. 1991 Dec 18;83(24):1797-805.

PMID:
1683908
40.

Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.

Fraschini G, Ciociola A, Esparza L, Templeton D, Holmes FA, Walters RS, Hortobagyi GN.

J Clin Oncol. 1991 Jul;9(7):1268-74.

PMID:
1828499
41.

Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia.

Kantarjian HM, Walters RS, Keating MJ, Smith TL, O'Brien S, Estey EH, Huh YO, Spinolo J, Dicke K, Barlogie B, et al.

J Clin Oncol. 1990 Jun;8(6):994-1004.

PMID:
2189958
42.

Pirarubicin in combination chemotherapy for metastatic breast cancer.

Hortobagyi GN, Theriault RL, Frye D, Walters RS, Fraschini G, Tashima CK, Ro JS, Salewski E, Buzdar AU.

Am J Clin Oncol. 1990;13 Suppl 1:S54-6.

PMID:
2291460
43.

Myeloid surface antigen-positive acute lymphoblastic leukemia (My+ ALL): immunophenotypic, ultrastructural, cytogenetic, and molecular characteristics.

Childs CC, Hirsch-Ginsberg C, Walters RS, Andersson BS, Reuben J, Trujillo JM, Cork A, Stass SA, Freireich EJ, Zipf TF.

Leukemia. 1989 Nov;3(11):777-83.

PMID:
2811478
44.

Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia.

Kantarjian HM, Walters RS, Keating MJ, Barlogie B, McCredie KB, Freireich EJ.

Cancer. 1989 Jul 1;64(1):16-22.

PMID:
2659160
45.

Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia.

Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ.

Cancer. 1989 Mar 1;63(5):813-7.

PMID:
2914287
46.

Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia.

Kantarjian HM, Walters RS, Smith TL, Keating MJ, Barlogie B, McCredie KB, Freireich EJ.

Blood. 1988 Nov;72(5):1784-9.

PMID:
3052630
47.

Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia.

Walters RS, Kantarjian HM, Keating MJ, Plunkett WK, Estey EH, Andersson B, Beran M, McCredie KB, Freireich EJ.

Cancer. 1988 Aug 15;62(4):677-82.

PMID:
3165047
48.

Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside.

Kantarjian HM, Walters RS, Keating MJ, Talpaz M, Andersson B, Beran M, McCredie KB, Freireich EJ.

Cancer. 1988 Aug 15;62(4):672-6.

PMID:
3165046
49.

Characteristics of accelerated disease in chronic myelogenous leukemia.

Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ.

Cancer. 1988 Apr 1;61(7):1441-6.

PMID:
3162181
50.

The characteristics and outcome of patients with late relapse acute myelogenous leukemia.

Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Freireich EJ.

J Clin Oncol. 1988 Feb;6(2):232-8.

PMID:
3276823

Supplemental Content

Loading ...
Support Center